Open an account

Aclarion

ACON · NASDAQ

$1.97+$0.08 (+4.23%)TodayMarket closed ·
Prev close $1.89

About ACON

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 11 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Employees
11
Headquarters
Broomfield, Colorado
Listed
Apr 22, 2022
Sector
Health Care
Industry
Health Care Technology
Website
aclarion.com

ACON key statistics

Market cap
5.68M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
41.62K
Volume
17.62K
Open price
$1.90
High today
$2.00
Low today
$1.88
52 Week high
$9.36
52 Week low
$1.85

Aclarion (ACON) at a glance

Aclarion (ACON) last traded at $1.97, with a market cap of 5.68M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.88 and $2.00. The current price is 4.7% above the day's low and 1.5% below its high.

Volume so far is 17.62K shares, below the average of 41.62K shares a day.

Over the past year Aclarion has ranged from $1.85 to $9.36, and now sits 2% of the way up that range.

Aclarion met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$1.12 per share against an estimate of -$1.07.

The average analyst price target is $7.65, 288.3% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $7.65
Low
$7.57
Now
$1.97
High
$7.88

ACON earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 38.1% on average.

  1. Q3 FY24: reported -$1,356.75 per share against an estimate of -$1,568.40
  2. Q4 FY24: reported -$786.70 per share against an estimate of -$1,153.24
  3. Q1 FY25: reported -$9.32 per share against an estimate of -$1,476.14
  4. Q2 FY25: reported -$2.75 per share against an estimate of -$2.31
  5. Q3 FY25: reported -$2.93 per share against an estimate of -$2.67
  6. Q4 FY25: reported -$2.54 per share against an estimate of -$3.67
  7. Q1 FY26: reported -$1.34 per share against an estimate of -$1.58
  8. Q2 FY26: reported -$1.12 per share against an estimate of -$1.07

ACON news

  • Press releaseGlobe Newswire

    Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

  • Press releaseGlobe Newswire

    Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

  • Press releaseGlobe Newswire

    Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026

  • Press releaseGlobe Newswire

    Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

  • Press releaseGlobe Newswire

    Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

  • Press releaseGlobe Newswire

    Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

  • Press releaseGlobe Newswire

    Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

  • Press releaseGlobe Newswire

    Aclarion Announces $2.5 Million Stock Repurchase Plan

Similar companies

Companies in the same industry as Aclarion

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.